“Commissioner Gottlieb was an exemplary public servant who used his experience as a physician and in the life sciences to create a regulatory balance at the FDA that ensured safe, new breakthrough therapies reached patients who need and deserve them. Amidst a partisan political environment, a government shutdown, and constant debate about drug pricing, Commissioner Gottlieb never missed a beat, oversaw a record number of new drug approvals in 2018, and implemented a range of regulatory reforms to get more generic drugs on the market. His legacy at the FDA is of real reform and creating new possibilities for sick people”
– Robert K. Coughlin, President and CEO of MassBio